A report of trazodone-associated laboratory abnormalities

Ther Drug Monit. 1990 Nov;12(6):517-9. doi: 10.1097/00007691-199011000-00001.

Abstract

A 6-week multicenter, double-blind, controlled study comparing the therapeutic efficacy of two antidepressant drugs, trazodone and fluoxetine, was conducted. The hematocrit, hemoglobin, red blood cell count, serum cholesterol, serum calcium, and serum albumin levels were all significantly decreased after six weeks of trazodone treatment. Similar findings were not obvious for the fluoxetine treatment group. Trazodone caused the development of a pseudoanemia in 36% of the trazodone treatment patients compared with 20% of the fluoxetine treatment patients. The anemia was not regarded as clinically significant. Of the decreases in the patients' chemistries, only the decrease in cholesterol could not be reconciled.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Multicenter Study

MeSH terms

  • Double-Blind Method
  • Erythrocyte Count / drug effects
  • Female
  • Fluoxetine / adverse effects*
  • Fluoxetine / therapeutic use
  • Hematocrit / standards
  • Hemoglobins / drug effects*
  • Humans
  • Male
  • Reference Values
  • Trazodone / adverse effects*
  • Trazodone / therapeutic use

Substances

  • Hemoglobins
  • Fluoxetine
  • Trazodone